These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29069327)

  • 1. The role of complement inhibition in kidney transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Frémeaux-Bacchi V
    Br Med Bull; 2017 Dec; 124(1):5-17. PubMed ID: 29069327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab in renal transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Rabant M; Loupy A; Timsit MO; Anglicheau D
    Transplant Rev (Orlando); 2013 Jul; 27(3):90-2. PubMed ID: 23747093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation.
    Java A
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):128-137. PubMed ID: 32553245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience.
    Kleiboeker HL; Prom A; Paplaczyk K; Myers CN
    Ann Pharmacother; 2024 Sep; 58(9):947-955. PubMed ID: 37994573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of complement inhibitors in transplantation.
    Frémeaux-Bacchi V; Legendre CM
    Kidney Int; 2015 Nov; 88(5):967-73. PubMed ID: 26376132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the complement cascade: novel treatments coming down the pike.
    Thurman JM; Le Quintrec M
    Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation.
    Berger M; Lefaucheur C; Jordan SC
    Transplantation; 2019 Sep; 103(9):1763-1775. PubMed ID: 30946220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement-Based Therapy in the Management of Antibody-Mediated Rejection.
    Bhalla A; Alachkar N; Alasfar S
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):138-148. PubMed ID: 32553246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.
    Jordan SC; Choi J; Kahwaji J; Vo A
    Transplant Proc; 2016 Apr; 48(3):806-8. PubMed ID: 27234741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
    Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
    Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
    Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement in renal transplantation: The road to translation.
    Jager NM; Poppelaars F; Daha MR; Seelen MA
    Mol Immunol; 2017 Sep; 89():22-35. PubMed ID: 28558950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
    Wijnsma KL; Duineveld C; Wetzels JFM; van de Kar NCAJ
    Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.